TRIT1: A Drug Target / Disease Biomarker (G54802)

Target Name: TRIT1

NCBI ID: G54802

TRIT1: A Drug Target / Disease Biomarker

TRIT1, also known as tripartite repeat-containing gene 1, is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The TRIT1 gene is located on chromosome 16 and encodes a protein known as TRIT1, which is composed of three repetitive nucleotide sequences. The repetitive nucleotide sequences in TRIT1 are thought to play a role in the regulation of cellular processes that are important for the survival and proliferation of cancer cells, including cell division, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Studies have suggested that TRIT1 may be involved in the development and progression of cancer, including breast, ovarian, and colorectal cancers. For example, researchers have found that high levels of TRIT1 are associated with poor prognosis in breast cancer patients, and that inhibiting TRIT1 may be a promising strategy for treating this disease.

In addition to its potential role in cancer, TRIT1 has also been suggested as a potential biomarker for neurodegenerative diseases. The repetitive nucleotide sequences in TRIT1 are thought to be involved in the regulation of cellular processes that are important for the survival and function of nerve cells, and thus may be useful for the diagnosis and monitoring of neurodegenerative diseases.

TRIT1 has also been suggested as a potential drug target for treating autoimmune disorders. The repetitive nucleotide sequences in TRIT1 may be involved in the regulation of immune cells, and thus may be a target for drugs that are used to treat autoimmune disorders.

While more research is needed to fully understand the role of TRIT1 in these diseases, the potential implications of targeting this gene with drugs are significant. If TRIT1 is indeed involved in the regulation of cellular processes that are important for the survival and function of cancer cells, inhibiting it may be a promising strategy for treating a variety of cancer types. In addition, if TRIT1 is involved in the regulation of immune cells, targeting it with drugs may be a promising strategy for treating autoimmune disorders.

Overall, TRIT1 is a gene that has significant potential as a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: TRNA Isopentenyltransferase 1

Functions: Catalyzes the transfer of a dimethylallyl group onto the adenine at position 37 of both cytosolic and mitochondrial tRNAs, leading to the formation of N6-(dimethylallyl)adenosine (i6A37) (PubMed:11111046, PubMed:24126054, PubMed:24901367, PubMed:34774131). Mediates modification of a limited subset of tRNAs: tRNA(Ser)(AGA), tRNA(Ser)(CGA), tRNA(Ser)(UGA), as well as partial modification of the selenocysteine tRNA(Ser)(UCA) (PubMed:24126054). TRIT1 is therefore required for selenoprotein expression (PubMed:24126054)

More Common Targets